Aethlon Medical(AEMD) - 2025 Q2 - Quarterly Report

Financial Performance - Total current assets increased to $7,138,083 as of September 30, 2024, up from$6,225,788 as of March 31, 2024, representing a growth of 14.6%[9] - Total liabilities rose to $2,828,222 as of September 30, 2024, compared to$2,479,650 as of March 31, 2024, indicating an increase of 14.1%[10] - The net loss for the three months ended September 30, 2024, was $2,806,973, a decrease from the net loss of$3,034,456 for the same period in 2023, reflecting an improvement of 7.5%[13] - Basic and diluted loss per share for the three months ended September 30, 2024, was $(0.20), compared to$(1.22) for the same period in 2023, showing a significant reduction in loss per share[13] - For the six months ended September 30, 2024, the net loss was $5,378,414, compared to a net loss of$6,316,635 for the same period in 2023, representing a 14.8% improvement in losses year-over-year[17] Cash and Assets - Cash and cash equivalents increased to $6,859,075 as of September 30, 2024, compared to$5,441,978 as of March 31, 2024, marking a rise of 26.0%[9] - The cash and restricted cash at the end of the period on September 30, 2024, was $6,946,581, compared to$10,263,426 at the end of the same period in 2023, reflecting a decrease in available cash[17] - The total stockholders' equity as of September 30, 2024, was $6,019,108, up from$5,766,332 as of March 31, 2024, reflecting an increase of 4.4%[11] - The accumulated deficit as of September 30, 2024, was $(159,945,141), compared to$(154,566,728) as of March 31, 2024, indicating an increase in the deficit[11] Operating Expenses - Total operating expenses for the six months ended September 30, 2024, were $5,521,856, down from$6,583,506 for the same period in 2023, a decrease of 16.2%[13] - Professional fees for the three months ended September 30, 2024, were $570,845, down from$1,133,111 for the same period in 2023, a decrease of 49.6%[13] - Payroll and related expenses for the three months ended September 30, 2024, increased to $1,372,899 from$1,191,426 in 2023, an increase of 15.2%[13] - The company reported total operating expenses of $2,902,119 for the three months ended September 30, 2024, down from$3,175,346 in the same period of 2023, a decrease of 8.61%[13] Research and Development - The company incurred research and development expenses of $261,486 for the three months ended September 30, 2024, compared to$628,447 for the same period in 2023, representing a decrease of approximately 58.4%[47] - For the six months ended September 30, 2024, research and development expenses totaled $702,115, down from$1,687,010 in the same period of 2023, indicating a reduction of about 58.3%[47] Clinical Trials and Product Development - The Hemopurifier has been designated as a "Breakthrough Device" by the FDA for treating advanced or metastatic cancer and life-threatening viral infections, highlighting its potential in critical medical applications[18] - Clinical trials for the Hemopurifier have commenced in Australia and India, focusing on safety, feasibility, and dose-finding in cancer patients, with trials involving approximately 9 to 18 patients in each country[20][22] - The company has established a wholly-owned subsidiary in Australia to conduct oncology-related clinical research and seek regulatory approval for the Hemopurifier[19] - The Hemopurifier has shown potential in removing harmful exosomes and exosomal particles, which may contribute to cancer progression and immune suppression[18] - The company has successfully enrolled the first two patients in its Australian clinical trial for the Hemopurifier, marking a significant milestone in its clinical program[85] Financing Activities - The company raised $5,384,307 from the issuance of common stock during the six months ended September 30, 2024, compared to$1,086,119 in the same period of 2023, indicating a significant increase in financing activities[17] - The company completed a public offering on May 17, 2024, raising gross proceeds of approximately $4.7 million, with net proceeds of about$3.5 million after deducting fees and expenses[55] Management and Governance - The company appointed James B. Frakes as the permanent CEO effective October 3, 2024, while also retaining his role as CFO[84] - In April 2024, the company granted 32,894 RSUs to each of the four eligible non-employee directors, with each RSU priced at $1.52 per share[59] - For the three months ended September 30, 2024, the company accrued$68,250 for board fees and paid out $68,250, compared to$57,000 paid in the same period in 2023[60] Legal and Regulatory Matters - The company is currently not involved in any litigation or pending legal proceedings, reflecting a stable legal environment[82] - The company has received ethics review board approval for its COVID-19 clinical trial at Medanta Medicity Hospital and Maulana Azad Medical College in India[29] Future Outlook - The company expects that existing cash as of September 30, 2024, will not be sufficient to fund operations for at least twelve months from the issuance date of its financial statements[43] - The company is closely monitoring the impact of global events such as inflation and military conflicts on its business operations and financial condition[33]